{"title":"用于牙槽骨缺损再生和修复的 RNA 技术。","authors":"D Su, S Swearson, S Eliason, K G Rice, B A Amendt","doi":"10.1177/00220345241242047","DOIUrl":null,"url":null,"abstract":"<p><p><i>microRNA-200a</i> (<i>miR-200a</i>) targets multiple signaling pathways that are involved in osteogenic differentiation and bone development. However, its therapeutic function in osteogenesis and bone regeneration remains unknown. In this study, we use in vitro and in vivo models to investigate the molecular function of <i>miR-200a</i> overexpression and <i>miR-200a</i> inhibition using a plasmid-based miR inhibitor system (PMIS) on osteogenic differentiation and bone regeneration. Inhibition of <i>miR-200a</i> using <i>PMIS-miR-200a</i> significantly increased osteogenic biomarkers of human embryonic palatal mesenchyme cells and promoted bone regeneration in rat tooth socket defects. In rat maxillary M1 molar extractions, the supporting tooth structures were removed with an implant drill to yield a 3-mm defect in the alveolar bone. A collagen sponge was inserted into the open alveolar defect and <i>PMIS-miR-200a</i> plasmid DNA was added to the sponge and the wound sutured to protect the sponge and close the defect. It was important to remove the existing tooth supporting structure, which can influence alveolar bone regeneration. The alveolar bone was regenerated in 4 wk. The collagen sponge acts to stabilize and deliver the <i>PMIS-miR-200a</i> DNA to cells entering the sponge in the bone defect. We show that mesenchymal stem cells expressing CD90 and Stro-1 enter the sponges, take up the DNA, and express <i>PMIS-miR-200a. PMIS-miR-200a</i> initiates a bone regeneration program in transformed cells in vivo. In vitro inhibition of <i>miR-200a</i> was found to upregulate Wnt and BMP signaling activity as well as <i>Runx2, OCN, Lef-1, Msx2</i>, and <i>Dlx5</i> associated with osteogenesis. Liver and blood toxicity testing of <i>PMIS-miR-200a</i>-treated rats showed no increase in several biomarkers of liver disease. These results demonstrate the therapeutic function of <i>PMIS-miR-200a</i> for rapid bone regeneration. Furthermore, the studies were designed to demonstrate the ease of use of <i>PMIS-miR-200a</i> in solution and applied using a syringe in the clinic through a simple one-time application.</p>","PeriodicalId":94075,"journal":{"name":"Journal of dental research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11122091/pdf/","citationCount":"0","resultStr":"{\"title\":\"RNA Technology to Regenerate and Repair Alveolar Bone Defects.\",\"authors\":\"D Su, S Swearson, S Eliason, K G Rice, B A Amendt\",\"doi\":\"10.1177/00220345241242047\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>microRNA-200a</i> (<i>miR-200a</i>) targets multiple signaling pathways that are involved in osteogenic differentiation and bone development. However, its therapeutic function in osteogenesis and bone regeneration remains unknown. In this study, we use in vitro and in vivo models to investigate the molecular function of <i>miR-200a</i> overexpression and <i>miR-200a</i> inhibition using a plasmid-based miR inhibitor system (PMIS) on osteogenic differentiation and bone regeneration. Inhibition of <i>miR-200a</i> using <i>PMIS-miR-200a</i> significantly increased osteogenic biomarkers of human embryonic palatal mesenchyme cells and promoted bone regeneration in rat tooth socket defects. In rat maxillary M1 molar extractions, the supporting tooth structures were removed with an implant drill to yield a 3-mm defect in the alveolar bone. A collagen sponge was inserted into the open alveolar defect and <i>PMIS-miR-200a</i> plasmid DNA was added to the sponge and the wound sutured to protect the sponge and close the defect. It was important to remove the existing tooth supporting structure, which can influence alveolar bone regeneration. The alveolar bone was regenerated in 4 wk. The collagen sponge acts to stabilize and deliver the <i>PMIS-miR-200a</i> DNA to cells entering the sponge in the bone defect. We show that mesenchymal stem cells expressing CD90 and Stro-1 enter the sponges, take up the DNA, and express <i>PMIS-miR-200a. PMIS-miR-200a</i> initiates a bone regeneration program in transformed cells in vivo. In vitro inhibition of <i>miR-200a</i> was found to upregulate Wnt and BMP signaling activity as well as <i>Runx2, OCN, Lef-1, Msx2</i>, and <i>Dlx5</i> associated with osteogenesis. Liver and blood toxicity testing of <i>PMIS-miR-200a</i>-treated rats showed no increase in several biomarkers of liver disease. These results demonstrate the therapeutic function of <i>PMIS-miR-200a</i> for rapid bone regeneration. Furthermore, the studies were designed to demonstrate the ease of use of <i>PMIS-miR-200a</i> in solution and applied using a syringe in the clinic through a simple one-time application.</p>\",\"PeriodicalId\":94075,\"journal\":{\"name\":\"Journal of dental research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11122091/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of dental research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/00220345241242047\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of dental research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00220345241242047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
RNA Technology to Regenerate and Repair Alveolar Bone Defects.
microRNA-200a (miR-200a) targets multiple signaling pathways that are involved in osteogenic differentiation and bone development. However, its therapeutic function in osteogenesis and bone regeneration remains unknown. In this study, we use in vitro and in vivo models to investigate the molecular function of miR-200a overexpression and miR-200a inhibition using a plasmid-based miR inhibitor system (PMIS) on osteogenic differentiation and bone regeneration. Inhibition of miR-200a using PMIS-miR-200a significantly increased osteogenic biomarkers of human embryonic palatal mesenchyme cells and promoted bone regeneration in rat tooth socket defects. In rat maxillary M1 molar extractions, the supporting tooth structures were removed with an implant drill to yield a 3-mm defect in the alveolar bone. A collagen sponge was inserted into the open alveolar defect and PMIS-miR-200a plasmid DNA was added to the sponge and the wound sutured to protect the sponge and close the defect. It was important to remove the existing tooth supporting structure, which can influence alveolar bone regeneration. The alveolar bone was regenerated in 4 wk. The collagen sponge acts to stabilize and deliver the PMIS-miR-200a DNA to cells entering the sponge in the bone defect. We show that mesenchymal stem cells expressing CD90 and Stro-1 enter the sponges, take up the DNA, and express PMIS-miR-200a. PMIS-miR-200a initiates a bone regeneration program in transformed cells in vivo. In vitro inhibition of miR-200a was found to upregulate Wnt and BMP signaling activity as well as Runx2, OCN, Lef-1, Msx2, and Dlx5 associated with osteogenesis. Liver and blood toxicity testing of PMIS-miR-200a-treated rats showed no increase in several biomarkers of liver disease. These results demonstrate the therapeutic function of PMIS-miR-200a for rapid bone regeneration. Furthermore, the studies were designed to demonstrate the ease of use of PMIS-miR-200a in solution and applied using a syringe in the clinic through a simple one-time application.